• Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas 

      Fack, Fred; Espedal, Heidi; Keunen, Olivier; Golebiewska, Anna; Obad, Nina; Harter, Patrick N.; Mittelbronn, Michel; Bähr, Oliver; Weyerbrock, Astrid; Stuhr, Linda Elin Birkhaug; Miletic, Hrvoje; Sakariassen, Per Øystein; Stieber, Daniel; Rygh, Cecilie Brekke; Lund-Johansen, Morten; Zheng, Liang; Gottlieb, Eyal; Niclou, Simone P.; Bjerkvig, Rolf (Peer reviewed; Journal article, 2015-01)
      Anti-angiogenic therapy in glioblastoma (GBM) has unfortunately not led to the anticipated improvement in patient prognosis. We here describe how human GBM adapts to bevacizumab treatment at the metabolic level. By performing ...
    • Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes 

      Stieber, Daniel; Golebiewska, Anna; Evers, Lisa; Lenkiewicz, Elizabeth; Brons, Nicolas H.C.; Nicot, Nathalie; Oudin, Anaïs; Bougnaud, Sébastien; Hertel, Frank; Bjerkvig, Rolf; Vallar, Laurent; Barrett, Michael T.; Niclou, Simone P. (Peer reviewed; Journal article, 2014-02)
      Glioblastoma (GBM) is known to be a heterogeneous disease; however, the genetic composition of the cells within a given tumour is only poorly explored. In the advent of personalised medicine the understanding of intra-tumoural ...
    • Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis 

      Schubert, Manja; Panja, Debabrata; Haugen, Mette; Bramham, Clive R.; Vedeler, Christian A. (Peer reviewed; Journal article, 2014-12)
      Paraneoplastic cerebellar degeneration (PCD) is characterized by loss of Purkinje cells (PCs) associated with progressive pancerebellar dysfunction in the presence of onconeural Yo antibodies. These antibodies recognize ...